Sutro Biopharma, Inc. (STRO)

Market Cap	154.61M
Revenue (ttm)	160.96M
Net Income (ttm)	-123.95M
Shares Out	82.46M
EPS (ttm)	-1.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	209,529
Open	1.900
Previous Close	1.880
Day's Range	1.845 - 1.920
52-Week Range	1.700 - 6.130
Beta	1.09
Analysts	Strong Buy
Price Target	12.14 (+547.47%)
Earnings Date	Nov 13, 2024

About STRO

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 302
• Stock Exchange: NASDAQ
• Ticker Symbol: STRO
• Website: https://www.sutrobio.com

Financial Performance

In 2023, Sutro Biopharma's revenue was $153.73 million, an increase of 126.84% compared to the previous year's $67.77 million. Losses were -$106.79 million, -10.41% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for STRO stock is "Strong Buy." The 12-month stock price forecast is $12.14, which is an increase of 547.47% from the latest price.

Price Target

$12.14

(547.47% upside)

Analyst Consensus: Strong Buy